$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

$ssy Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000156459022037559 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$14.39M	$11.04M	$10.53M
YoY Change	38.24%	4.86%	0.99%
Cost Of Revenue	$4.518M	$4.369M	$4.073M
YoY Change	12.5%	7.27%	0.07%
Gross Profit	$9.874M	$6.668M	$6.452M
YoY Change	54.4%	3.35%	1.57%
Gross Profit Margin	68.61%	60.41%	61.3%
Selling, General & Admin	$6.193M	$6.820M	$6.030M
YoY Change	3.22%	13.1%	11.13%
% of Gross Profit	62.72%	102.28%	93.46%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$387.0K	$368.0K	$333.0K
YoY Change	5.74%	10.51%	11.0%
% of Gross Profit	3.92%	5.52%	5.16%
Operating Expenses	$7.834M	$8.281M	$7.445M
YoY Change	4.91%	11.23%	11.54%
Operating Profit	$2.040M	-$1.613M	-$993.0K
YoY Change	-290.3%	62.44%	207.43%
Interest Expense	$9.000K	-$4.000K	-$14.00K
YoY Change	-400.0%	-71.43%	100.0%
% of Operating Profit	0.44%
Other Income/Expense, Net
YoY Change
Pretax Income	$2.051M	-$1.544M	$2.008M
YoY Change	-551.76%	-176.89%	-790.03%
Income Tax	$1.000K	$0.00	$2.000K
% Of Pretax Income	0.05%		0.1%
Net Earnings	$1.951M	-$1.558M	$1.939M
YoY Change	-429.01%	-180.35%	-670.29%
Net Earnings / Revenue	13.56%	-14.12%	18.42%
Basic Earnings Per Share	$0.28	-$0.22	$0.28
Diluted Earnings Per Share	$0.28	-$0.22	$273.3K
COMMON SHARES
Basic Shares Outstanding	7.032M	7.032M	6.924M
Diluted Shares Outstanding	7.033M	6.983M	7.095M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.156M	$4.951M	$8.933M
YoY Change	-37.99%	-44.58%	-21.66%
Cash & Equivalents	$5.156M	$4.951M	$8.933M
Short-Term Investments
Other Short-Term Assets	$1.844M	$2.166M	$2.291M
YoY Change	-4.36%	-5.46%	-6.68%
Inventory	$1.812M	$1.842M	$1.917M
Prepaid Expenses
Receivables	$4.475M	$4.686M	$4.687M
Other Receivables	$1.737M	$1.761M	$3.586M
Total Short-Term Assets	$15.02M	$15.41M	$21.41M
YoY Change	-25.19%	-28.06%	6.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.427M	$8.482M	$6.920M
YoY Change	0.02%	22.57%	6.54%
Goodwill
YoY Change
Intangibles	$1.188M	$1.195M	$1.220M
YoY Change		-2.05%
Long-Term Investments
YoY Change
Other Assets	$496.0K	$630.0K	$649.0K
YoY Change	7.36%	-2.93%	33.81%
Total Long-Term Assets	$11.15M	$11.42M	$9.954M
YoY Change	10.34%	14.73%	20.99%
TOTAL ASSETS
Total Short-Term Assets	$15.02M	$15.41M	$21.41M
Total Long-Term Assets	$11.15M	$11.42M	$9.954M
Total Assets	$26.17M	$26.83M	$31.37M
YoY Change	-13.3%	-14.48%	11.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.876M	$1.831M	$1.698M
YoY Change	61.58%	7.83%	5.2%
Accrued Expenses	$3.258M	$5.822M	$5.296M
YoY Change	-35.41%	9.93%	18.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$30.00K	$41.00K	$37.00K
YoY Change	-21.05%	10.81%	-97.36%
Total Short-Term Liabilities	$5.633M	$8.163M	$7.545M
YoY Change	-18.01%	8.19%	-37.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$3.000K	$44.00K
YoY Change	-100.0%	-93.18%	-97.74%
Other Long-Term Liabilities	$182.0K	$114.0K	$1.030M
YoY Change	-82.99%	-88.93%	495.38%
Total Long-Term Liabilities	$975.0K	$1.053M	$1.074M
YoY Change	-11.84%	-1.96%	-61.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.633M	$8.163M	$7.545M
Total Long-Term Liabilities	$975.0K	$1.053M	$1.074M
Total Liabilities	$6.608M	$9.216M	$8.619M
YoY Change	-17.15%	6.93%	-41.93%
SHAREHOLDERS EQUITY
Retained Earnings	$5.193M	$3.242M
YoY Change
Common Stock	$14.26M	$14.26M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.56M	$17.61M	$22.75M
YoY Change
Total Liabilities & Shareholders Equity	$26.17M	$26.83M	$31.37M
YoY Change	-13.3%	-14.48%	11.06%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	$1.951M	-$1.558M	$1.939M
YoY Change	-429.01%	-180.35%	-670.29%
Depreciation, Depletion And Amortization	$387.0K	$368.0K	$333.0K
YoY Change	5.74%	10.51%	11.0%
Cash From Operating Activities	$546.0K	-$1.271M	-$334.0K
YoY Change	160.0%	280.54%	-141.03%
INVESTING ACTIVITIES
Capital Expenditures	$527.0K	$624.0K	$692.0K
YoY Change	-36.2%	-9.83%	16.3%
Acquisitions
YoY Change
Other Investing Activities	$151.0K	$51.00K	$5.000K
YoY Change	2416.67%	920.0%	-37.5%
Cash From Investing Activities	-$376.0K	-$562.0K	-$687.0K
YoY Change	-54.15%	-18.2%	17.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$10.00K	$8.000K
YoY Change		25.0%	0.0%
Cash From Financing Activities	35.00K	-10.00K	-8.000K
YoY Change	-537.5%	25.0%	0.0%
NET CHANGE
Cash From Operating Activities	546.0K	-1.271M	-334.0K
Cash From Investing Activities	-376.0K	-562.0K	-687.0K
Cash From Financing Activities	35.00K	-10.00K	-8.000K
Net Change In Cash	205.0K	-1.843M	-1.029M
YoY Change	-133.17%	79.11%	-569.86%
FREE CASH FLOW
Cash From Operating Activities	$546.0K	-$1.271M	-$334.0K
Capital Expenditures	$527.0K	$624.0K	$692.0K
Free Cash Flow	$19.00K	-$1.895M	-$1.026M
YoY Change	-103.08%	84.7%	-568.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	40000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1520000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	354000
CY2022Q3	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtCurrent
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtNoncurrent
CY2022Q3	dei	Local Phone Number LocalPhoneNumber	933-7000
CY2022Q3	us-gaap	Inventory Net InventoryNet	1842000
CY2022Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	4686000
CY2022Q2	ssy	Employee Retention Credits Receivable Current EmployeeRetentionCreditsReceivableCurrent	1761000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	857000
CY2022Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6794000
CY2022Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000096793
CY2022Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q3	dei	Entity File Number EntityFileNumber	1-12607
CY2022Q3	dei	Entity Registrant Name EntityRegistrantName	SUNLINK HEALTH SYSTEMS, INC.
CY2022Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Circle 75 Parkway
CY2022Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 690
CY2022Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Atlanta
CY2022Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30339
CY2022Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q3	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7031603
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4951000
CY2022Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	us-gaap	Inventory Net InventoryNet	1748000
CY2022Q3	ssy	Employee Retention Credits Receivable Current EmployeeRetentionCreditsReceivableCurrent	1761000
CY2022Q3	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	87000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1201000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1113000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1187000
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	630000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	523000
CY2022Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2911000
CY2022Q2	us-gaap	Assets Assets	27943000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1831000
CY2022Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	41000
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1347000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8163000
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3000
CY2022Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	86000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1888000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	15406000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	16815000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23920000
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15377000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15703000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8482000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8217000
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1195000
CY2022Q3	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2938000
CY2022Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2777000
CY2022Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2600000
CY2022Q2	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	519000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	352000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1313000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7691000
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	780000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11037000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10525000
CY2021Q3	us-gaap	Supplies Expense SuppliesExpense	300000
CY2021Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4698000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9962000
CY2021Q3	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8278000
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	90000
CY2022Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
CY2022Q3	ssy	Finance Lease Cost FinanceLeaseCost	10000
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M28D
CY2022Q3	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	108000
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	41000
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3000
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	91000
CY2022Q3	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	1000
CY2022Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10000
CY2022Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7000
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	203000
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0101
CY2022Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2022Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentGross
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentGross
CY2022Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtCurrent
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtNoncurrent
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	OH
CY2022Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-0621189
CY2022Q3	dei	City Area Code CityAreaCode	770
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	4624000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2166000
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23859000
CY2022Q3	us-gaap	Assets Assets	26826000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1347000
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1344000
CY2022Q3	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	469000
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	69000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	69000
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	114000
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106000
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1053000
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1132000
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2022Q2	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	2000000
CY2022Q3	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	2000000
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7032000
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7032000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6954000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6954000
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	3516000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3478000
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10746000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10736000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3242000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4800000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	106000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	106000
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17610000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19120000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26826000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27943000
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	5330000
CY2022Q3	us-gaap	Supplies Expense SuppliesExpense	337000
CY2022Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1093000
CY2021Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1082000
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	118000
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	170000
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	368000
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	333000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1613000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-993000
CY2022Q3	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	12000
CY2021Q3	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	5000
CY2022Q3	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	0
CY2021Q3	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	3010000
CY2022Q3	ssy	Federal Stimulus Provider Relief Funds FederalStimulusProviderReliefFunds	61000
CY2021Q3	ssy	Federal Stimulus Provider Relief Funds FederalStimulusProviderReliefFunds	0
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4000
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-14000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1544000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2008000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1544000
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2006000
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-14000
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-67000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1558000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1939000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1558000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1939000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.22
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.29
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.22
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.28
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2021Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6983000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6924000
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6983000
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7095000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19120000
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1558000
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17610000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20810000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1939000
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	22749000
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1271000
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-334000
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	624000
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	692000
CY2022Q3	ssy	Proceeds From Share Option Exercises ProceedsFromShareOptionExercises	49000
CY2021Q3	ssy	Proceeds From Share Option Exercises ProceedsFromShareOptionExercises	0
CY2022Q3	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	13000
CY2021Q3	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	5000
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-562000
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-687000
CY2022Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10000
CY2021Q3	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8000
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10000
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1843000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1029000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6794000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4951000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8933000
CY2022Q3	ssy	Interest Paid Received Net InterestPaidReceivedNet	4000
CY2021Q3	ssy	Interest Paid Received Net InterestPaidReceivedNet	-1000
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
CY2021Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-293000
CY2022Q3	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	7000
CY2021Q3	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	35000
CY2022Q3	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2. – Business Operations </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Services</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Health Services segment includes the following:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">A subsidiary which owns and operates Trace Regional Medical Center (“Trace”) which is composed of an 49 licensed-bed acute care hospital, located in Houston, Mississippi. Our Medical Center includes an 26-bed geriatric psychology unit (“GPU”) and an attached 66-bed extended care and rehabilitation center. This facility focuses primarily on senior healthcare services.</span> </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">A subsidiary, SunLink Health Systems Technology (“SHS Technology”), which provides information technology (“IT”) services to outside customers and to SunLink subsidiaries.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman'">A</span><span style="font-size:10pt;font-family:'Times New Roman'"> </span><span style="font-family:Times New Roman;">subsidiary which owns approximately five (5) acres of unimproved land in Houston, Mississippi, and</span> </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.12%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"> </span><span style="font-family:'Times New Roman';color:#000000;"><span style="font-size:10pt;font-family:'Times New Roman'">A</span><span style="font-size:10pt;font-family:'Times New Roman'"> </span></span><span style="color:#000000;">subsidiary which owns approximately 25 acres of unimproved land in Ellijay, Georgia.</span></p></td></tr></table></div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmacy</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pharmacy segment is composed of three operational areas:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Retail pharmacy products and services, consisting of retail pharmacy sales conducted in rural markets at two locations in Louisiana. This also includes non-institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings, including private residences in Louisiana; </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;">Institutional pharmacy services consisting of the provision of specialty and non-specialty</span><span style="font-family:Times New Roman;"> p</span><span style="font-family:Times New Roman;">harmaceutical and biological products to institutional clients or to patients in institutional settings, such as </span><span style="font-family:Times New Roman;">extended care and rehabilitation centers, nursing homes</span><span style="font-family:Times New Roman;">, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities</span><span style="font-family:Times New Roman;">; </span><span style="font-family:Times New Roman;">and,</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"> </p></td> <td style="width:4.25%;white-space:nowrap" valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman'"> </span><span style="font-size:10pt;font-family:'Times New Roman'"> </span><span style="font-family:Times New Roman;">Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</span></p></td></tr></table></div> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#212529;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">COVID-19 Pandemic and CARES Act Funding</span></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. We have continued to monitor the impact on our operations of the COVID-19 pandemic and its aftermath and have taken significant steps intended to minimize the risk to our employees and patients. Certain employees have been working remotely, but we believe these remote work arrangements have not materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with, among other things, our understanding of applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic, although such protocols and guidance have been subject to changes and at times have been unclear. Nevertheless, as in many healthcare environments, we have experienced disruption of our operations, COVID-19 illness, including deaths, and some employees have tested positive and were placed on leave or in quarantine. We believe the effect of the COVID-19 pandemic and certain public and certain governmental responses to it have negatively affected our last eleven quarter’s results. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late December 2020, we began receiving allotments of COVID-19 vaccine and have vaccinated patients, providers, employees, and staff in accordance with the protocols and guidelines in the states where we operate. Not all such individuals have been vaccinated to date and some individuals have not consented to vaccination. The Company and its subsidiaries are currently developing and will implement plans to vaccinate employees to the extent required by the final rules of CMS. The Company believes the vaccine mandates have resulted in the loss of staff, including clinical staff, and together with the current state of the labor market, have negatively affected the Company’s ability to maintain the current levels of service. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:6.25%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our Healthcare Segment business, we have experienced material reductions in demand and net revenues due to the COVID-19 pandemic and its aftermath. There continues to be reduced current demand for certain hospital services and for extended care, rehabilitation center and nursing home admissions and clinic visits. The availability and cost of medical supplies have adversely affected our Healthcare businesses and we continue to monitor supplies and seek additional sources of many supply items. A reduction in the availability of qualified employees accompanied by an increase in the levels of salaries, wages and benefits have occurred, and, despite good faith efforts to do so, we have not yet been able to rehire or fully replace staff reductions which were previously furloughed, laid off or retired.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the COVID-19 pandemic and its aftermath, our Pharmacy business has experienced reduced sales trends in certain areas, increased costs and reduced staff. Many of our primary physician referral sources have been operating at reduced capacity, and until these referral sources resume operating at full capacity, we believe the COVID-19 pandemic will have continuing to effects on the demand for DME products and Retail and Institutional Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Extended care facilities and rehabilitation centers, nursing homes and other customers of our Institutional Pharmacy services continue to be adversely affected by the COVID-19 pandemic. Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. The impact of the COVID-19 pandemic and its aftermath also has and continues to have negatively affected our supply processes and costs generally.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:5.88%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Healthcare and Pharmacy segments have received approximately $6,182 in general and targeted Provider Relief Funds ("PRF") during the period April 1, 2020 through September 30, 2022 under the CARES Act, which was enacted in March 2020 in response to the COVID-19 pandemic. The PRF distributions have been accounted for as government grants, and a total of $5,715 have been recognized since April l, 2020 as other income under the gain contingency recognition method.</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:5.88%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:5.88%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the quarter ended June 30, 2020, our Healthcare and Pharmacy segments received $3,234 in Paycheck Protection Plan (“PPP”) loans provided under the CARES Act. These loans were forgivable upon </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compliance with conditions specified under the PPP loan program. As of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30, 2022, all our PPP loans have been forgiven.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.25%;">The Taxpayer Certainty and Disaster Tax Relief Act of 2020, enacted December 27, 2020, made a number of changes to employer retention tax credits previously made available under the CARES Act, including modifying and extending the Employee Retention Credit ("ERC") for the six calendar months ending June 30, 2021. As a result of such legislation, the Company qualified for ERC for the first and second calendar quarters of 2021 due to the decrease in its gross receipts and has applied for ERC of $3,586 through amended quarterly payroll tax filings for the applicable quarters. Through the date of this filing, the Company has received $1,803 of ERC which we applied for. We continue to monitor compliance with the terms and conditions of the ERC and PPP programs and developing interpretations and enforcement of the ERC and PPP program rules and the regulations. </p> <p style="margin-bottom:12pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;text-indent:0%;color:#1B1B1B;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="margin-left:36pt;"/><span style="color:#000000;">PRF distributions are subject to Federal audits and Single Audits and not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for designated, allowable healthcare-related expenses and capital expenditures attributable to COVID-19 and for "Lost Revenues" as defined by the department of “HHS”. We continue to monitor compliance with the terms and conditions of the PRF and developing interpretations and enforcement of PRF rules and regulations, as well as the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the PRF received may be impacted, and we may have to return the unutilized portion of those funds, if any, in the future. The Company filed its Schedule of Grant Income of HHS awards and audit report for the year ended June 30, 2021 with the Health Resources and Services Administration (“HRSA”) agency of HHS on September 30, 2022. </span></p> <p style="margin-bottom:12pt;margin-top:0pt;margin-left:0.3%;margin-right:0.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.25%;">The Company is unable to determine the extent to which the COVID-19 pandemic and its aftermath will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited. The nature and extent of the continuing effect of the COVID-19 pandemic and its aftermath on our balance sheet and results of operations will depend on the severity and length of the pandemic or to evolving strains of COVID-19; any further government actions to address the pandemic's continuing effect; regulatory changes in response to the pandemic, especially those that affect our hospital, extended care, rehabilitation center, nursing home, clinics, and our pharmacy operations; existing and potential government assistance that may be provided; and the requirements of PRF, including our ability to retain such PRF received.</p>
	ssy	Employee Retention Credit Amending Quarterly Payroll Tax Filing Amount EmployeeRetentionCreditAmendingQuarterlyPayrollTaxFilingAmount	3586000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2022Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	77452
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11037000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10525000
CY2022Q3	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	0
CY2021Q3	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	0
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6000
CY2022Q3	ssy	Finance Lease Obligations FinanceLeaseObligations	44000
CY2022Q2	ssy	Finance Lease Obligations FinanceLeaseObligations	54000
CY2022Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	41000
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	40000
CY2022Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	3000
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	14000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q3	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2022Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	23143000
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	23143000
CY2022Q3	ssy	Net Operating Loss Carry Forwards Expire Period NetOperatingLossCarryForwardsExpirePeriod	2023 through fiscal 2038
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	125000
CY2022Q3	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	27000
CY2021Q3	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	44000
CY2022Q3	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	1000
CY2021Q3	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	1000
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	118000
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	170000
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	9000
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	9000
CY2021Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
CY2021Q3	ssy	Finance Lease Cost FinanceLeaseCost	10000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1113000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1187000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	203000
CY2022Q2	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	101000
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	40000
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	14000
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	126000
CY2021Q3	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	1000
CY2021Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	9000
CY2021Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	35000
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M28D
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M7D
CY2021Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y11M12D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0135
CY2021Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	359000
CY2022Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	42000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	351000
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	327000
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	124000
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11000
CY2022Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2022Q3	ssy	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	0
CY2022Q3	ssy	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	0
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1172000
CY2022Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	45000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	38000
CY2022Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1134000
CY2022Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	44000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	354000
CY2022Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	41000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	780000
CY2022Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3000
CY2022Q3	ssy	Number Of Taxing Authorities NumberOfTaxingAuthorities	2
CY2020Q2	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	359000
CY2022Q3	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	1500000
CY2022Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2777000
CY2022Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2600000
CY2022Q3	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11037000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1613000
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	368000
CY2022Q3	us-gaap	Assets Assets	26826000
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	624000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10525000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-993000
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	333000
CY2021Q3	us-gaap	Assets Assets	33368000
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	692000

Files In Submission

Name	View Source	Status
0001564590-22-037559-index-headers.html	Edgar Link	pending
0001564590-22-037559-index.html	Edgar Link	pending
0001564590-22-037559.txt	Edgar Link	pending
0001564590-22-037559-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ssy-10q_20220930.htm	Edgar Link	pending
ssy-20220930.xsd	Edgar Link	pending
ssy-ex311_9.htm	Edgar Link	pending
ssy-ex312_6.htm	Edgar Link	pending
ssy-ex321_8.htm	Edgar Link	pending
ssy-ex322_7.htm	Edgar Link	pending
ssy-20220930_def.xml	Edgar Link	unprocessable
ssy-20220930_lab.xml	Edgar Link	unprocessable
ssy-20220930_cal.xml	Edgar Link	unprocessable
ssy-20220930_pre.xml	Edgar Link	unprocessable
ssy-10q_20220930_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

2022 Q4 Form 10-Q Financial Statement

#000156459022037559 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY SUNLINK HEALTH SYSTEMS INC Stock $ssy

2022 Q4 Form 10-Q Financial Statement

#000156459022037559 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy